Recursion Pharma CEO Gibson sells $604k in shares

Recursion Pharmaceuticals (NASDAQ:RXRX), a $2.3 billion market cap biotech company currently trading at $5.31, saw Chief Executive Officer Christopher Gibson sell 100,000 shares of Class A Common Stock on October 10, 2025, at a price of $6.04, totaling $604,000. According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt, though it’s currently experiencing rapid cash burn.

The transaction was executed under a Rule 10b5-1 trading plan adopted on May 12, 2025. On the same day, Gibson also converted 120,000 shares of Class B Common Stock into Class A Common Stock. Additionally, a gift of 20,000 shares of Class A Common Stock was made. The stock has shown strong momentum with a 18% gain over the past six months, despite trading below its 52-week high of $12.36.

Following these transactions, Gibson directly owns 974,229 shares of Recursion Pharmaceuticals’ Class A Common Stock. He also indirectly owns 386,000 shares of Class B Common Stock through LAHWRAN-3 LLC, 388,000 shares through LAHWRAN-4 LLC and 50,000 shares through the Gibson Family Trust. Gibson also holds options to purchase shares of Class A Common Stock. For deeper insights into RXRX’s valuation and 12+ additional ProTips, access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Recursion Pharmaceuticals announced its second-quarter 2025 earnings, revealing a mixed financial performance. The company’s revenue significantly surpassed expectations, reaching $19.22 million against a forecast of $15.37 million, marking a 25.05% positive surprise. However, the earnings per share (EPS) did not meet projections, posting an actual EPS of -$0.41 compared to the anticipated -$0.35, resulting in a 17.14% negative surprise. These developments indicate a robust revenue performance, though challenges remain on the earnings front. The revenue beat suggests strong operational execution, while the EPS miss highlights areas needing improvement. Despite the mixed results, these figures reflect recent developments in Recursion Pharmaceuticals’ financial landscape. Investors may be encouraged by the revenue growth, even as the company works to address earnings challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.